FARMAKOKINETIKA GLIKLAZID DAN SIPROFLOKSASIN PADA PEMBERIAN BERSAMA DI TIKUS NORMAL YANG MENJALANI DIALISIS PERITONEAL

• Main Author: Luthfi Hanifah, Amyra
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/45221
• Institution: Institut Teknologi Bandung

One of the most common complications in patients with DM is a disorder of renal function, known as diabetic nephrophaty. Diabetic nephropathy could be also worsened by urinary tract infection. Ciprofloxacin and gliclazide are the medication that commonly used in that condition. This current study was aim to determine the pharmacokinetics of single dose gliclazide and ciprofloxacin and its combination in male Wistar rats experienced peritoneal dialysis, considering that in clinical applications of diabetic nephropathy patients who also have to undergo dialysis regularly. Rats were divided into 3 groups, group I was given a solution of ciprofloxacin (103 mg/kg), group II was given a suspension of gliclazide (33 mg/kg), and group III was given both gliclazide and ciprofloxacin concurrently. Blood and dialysate fluid samples were collected at the predetermined sampling points, then the samples were analyzed by HPLC and its pharmacokinetic parameters were determined. Pharmacokinetic parameters of ciprofloxacin for group I and group III showed significant differences (p<0.05), an increase in biological half-life (5.42 ± 1.02 to 15.24 ± 5.30 h), AUC0-????(4.12 ± 1.13 to 21.86 ± 10.51 µg.h/mL) and a decrease in clearance (26.74 ± 8.01 to 5.55 ± 2.3 L/jam.kg). There was no significant differences for gliclazide (group II and group III). Administration of gliclazide simultaneously with a single dose of ciprofloxacin in peritoneal dialysis rats caused a significant impact on pharmacokinetics of ciprofloxacin, but not on pharmacokinetics of gliclazide. Changes on pharmacokinetics of ciprofloxacin occurred in normal rat experienced peritoneal dialysis was in line with those not experienced peritoneal dialysis.